中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
4期
373-376
,共4页
沙美特罗氟替卡松粉吸入剂%慢性阻塞性肺疾病
沙美特囉氟替卡鬆粉吸入劑%慢性阻塞性肺疾病
사미특라불체잡송분흡입제%만성조새성폐질병
Fluticasone salmeterol powder inhaler%Chronic obstructive pulmonary disease
目的 观察不同剂型的沙美特罗氟替卡松粉吸入剂(舒利迭)(沙美特罗/丙酸氟替卡松:50 μg/500μg与沙美特罗/丙酸氟替卡松:50μg/250μg))在慢性阻塞性肺疾病(COPD)稳定期中的疗效.方法 将60例中、重度COPD患者随机分为治疗组和对照组.对照组给予舒利迭(50 μg/250μg),每12小时1次,疗程24周；治疗组给予吸入舒利迭(50 μg/500μg),每12小时1次,疗程24周.观察治疗前、后肺功能的变化,并进行临床症状问卷调查及体征检查评分.结果 治疗前,两组各项指标差异均无统计学意义(P均＞0.05).治疗后,治疗组临床症状体征评分显著低于对照组,差异有统计学意义[(4.0±0.5)分与(4.8±0.3)分,t =2.63,P＜0.05]；治疗组6min步行距离(6MWD)显著高于对照组,差异有统计学意义[(451.6±22.9)m与(401.2±25.4)m,t=2.51,P＜0.05]；治疗组的第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占预计值百分比(FEV1/预计值％)、第1秒用力呼气容积/用力肺活量(FEV1/FVC)均高于对照组,差异均有统计学意义[FEV1:治疗组(2.18±0.38)L,对照组(1.78±0.45)L；FEV1/预计值％:治疗组(63.19±9.08)％,对照组(57.19±9.25)％；FEV1/FVC:治疗组(73.8±5.6)％,对照组(67.3±11.5)％.t值分别为:2.61、2.48、2.52,P均＜0.05].结论 高剂量的舒利迭更能有效地改善中、重度慢性阻塞性肺疾病患者的肺功能指标,改善患者临床症状,改善生命质量.
目的 觀察不同劑型的沙美特囉氟替卡鬆粉吸入劑(舒利迭)(沙美特囉/丙痠氟替卡鬆:50 μg/500μg與沙美特囉/丙痠氟替卡鬆:50μg/250μg))在慢性阻塞性肺疾病(COPD)穩定期中的療效.方法 將60例中、重度COPD患者隨機分為治療組和對照組.對照組給予舒利迭(50 μg/250μg),每12小時1次,療程24週；治療組給予吸入舒利迭(50 μg/500μg),每12小時1次,療程24週.觀察治療前、後肺功能的變化,併進行臨床癥狀問捲調查及體徵檢查評分.結果 治療前,兩組各項指標差異均無統計學意義(P均＞0.05).治療後,治療組臨床癥狀體徵評分顯著低于對照組,差異有統計學意義[(4.0±0.5)分與(4.8±0.3)分,t =2.63,P＜0.05]；治療組6min步行距離(6MWD)顯著高于對照組,差異有統計學意義[(451.6±22.9)m與(401.2±25.4)m,t=2.51,P＜0.05]；治療組的第1秒用力呼氣容積(FEV1)、第1秒用力呼氣容積佔預計值百分比(FEV1/預計值％)、第1秒用力呼氣容積/用力肺活量(FEV1/FVC)均高于對照組,差異均有統計學意義[FEV1:治療組(2.18±0.38)L,對照組(1.78±0.45)L；FEV1/預計值％:治療組(63.19±9.08)％,對照組(57.19±9.25)％；FEV1/FVC:治療組(73.8±5.6)％,對照組(67.3±11.5)％.t值分彆為:2.61、2.48、2.52,P均＜0.05].結論 高劑量的舒利迭更能有效地改善中、重度慢性阻塞性肺疾病患者的肺功能指標,改善患者臨床癥狀,改善生命質量.
목적 관찰불동제형적사미특라불체잡송분흡입제(서리질)(사미특라/병산불체잡송:50 μg/500μg여사미특라/병산불체잡송:50μg/250μg))재만성조새성폐질병(COPD)은정기중적료효.방법 장60례중、중도COPD환자수궤분위치료조화대조조.대조조급여서리질(50 μg/250μg),매12소시1차,료정24주；치료조급여흡입서리질(50 μg/500μg),매12소시1차,료정24주.관찰치료전、후폐공능적변화,병진행림상증상문권조사급체정검사평분.결과 치료전,량조각항지표차이균무통계학의의(P균＞0.05).치료후,치료조림상증상체정평분현저저우대조조,차이유통계학의의[(4.0±0.5)분여(4.8±0.3)분,t =2.63,P＜0.05]；치료조6min보행거리(6MWD)현저고우대조조,차이유통계학의의[(451.6±22.9)m여(401.2±25.4)m,t=2.51,P＜0.05]；치료조적제1초용력호기용적(FEV1)、제1초용력호기용적점예계치백분비(FEV1/예계치％)、제1초용력호기용적/용력폐활량(FEV1/FVC)균고우대조조,차이균유통계학의의[FEV1:치료조(2.18±0.38)L,대조조(1.78±0.45)L；FEV1/예계치％:치료조(63.19±9.08)％,대조조(57.19±9.25)％；FEV1/FVC:치료조(73.8±5.6)％,대조조(67.3±11.5)％.t치분별위:2.61、2.48、2.52,P균＜0.05].결론 고제량적서리질경능유효지개선중、중도만성조새성폐질병환자적폐공능지표,개선환자림상증상,개선생명질량.
Objective To compare the clinical efficacy of seretide (50 μg/500 μg salmeterol/fluticasone propionate) with seretide (50 μg/250 μg salmeterol/fluticasone propionate) in single inhaler in the treatment of patients with stable status moderate to severe chronic obstructive pulmonary disease (COPD)Methods Sixty patients with COPD were randomly divided into the treatment and the control groups.Baseline treatments were similar in all patients,patients in the treatment group received seretide (50 μg/500 μg) while the control group received seretide (50 μg/250 μg) inhalation once every 12 hours for 24 weeks Before and after the therapeutic course,tests for lung function in patients of the two groups were conducted and compared with each other.Clinical symptoms and physical signs were graded by questionnaire.Results There was no significant difference on indexes of lung function between the two groups at baseline (P ＞ 0.05).After treatment,the score of clinical symptoms and signs in the treatment group was lower than that in the control group ((4.0 ± 0.5) vs.(4.8 ± 0.3),t =2.63,P ＜ 0.05).Six minutes walking distance was longer in the treatment group than that in the control group ((451.6±22.9) meter vs.(401.2 ±25.4) meter,t =2.51,P ＜0.05).The levels of forced exhaled gas volume 1 (FEV1),FEV1/forced vital capacity (FVC) and FEV1/pred in the treatment group were higher than those in the control group ([FEV1:(2.18 ± 0.38) L vs.(1.78 ± 0.45) L;FEV1/pred:(63.19 ±9.08)％ vs.(57.19 ±9.25)％; FEV1/FVC％:(73.8 ±5.6)％ vs.(67.3 ± 11.5)％ ;P ＜ 0.05).Conclnsion High dosage of seretide had better effect in the treatment of stable moderate and severe COPD,and can obviously improve patients' lung function,clinical symptoms and quality of life.
